Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...

What do you think is worth looking out for in the future for myelofibrosis? I thought we could focus first on non–drug-related research that is needed to move the field forward. What do you ...

Myelofibrosis is a rare cancer that affects your bone marrow, the spongy tissue inside some of your bones. In a healthy person, stem cells in the bone marrow make the red blood cells, white blood ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

The funding is set to support various activities, including the launch of a confirmatory study of bitopertin for ...

Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on November 6 and set ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...